BioPharmSignal logoBioPharmSignal

Biotech News

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana plc (NCNA)NuCana plcEarnings

Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom,

Related news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-06-01 12:00 EST

NuCana Appoints Ian Webster as Chief Financial Officer

NCNANuCana plc2026-05-14 20:01 EST

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-03-19 20:01 EST

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NCNANuCana plc2026-01-06 13:00 EST

NuCana Appoints Theresa Bruce as Chief Operating Officer

Stock data

Close
1.52 USD
Market cap
8.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States